Drug intelligence / Profile preview

SON-3015

Development stage: Unknown
Lead developer: Sonnet BioTherapeutics
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
Administration: Intravenous, Subcutaneous

Overview

SON-3015 is a preclinical-stage bifunctional biologic candidate developed by Sonnet BioTherapeutics for the treatment of solid tumors and bone metastases. It is engineered using the company's proprietary Fully Human Albumin Binding (FHAB) platform, which utilizes a human single-chain antibody fragment (scFv) to bind to serum albumin. This mechanism is designed to extend the drug's half-life and enhance its accumulation within the tumor microenvironment. SON-3015 simultaneously targets and inhibits Interleukin-6 (IL-6) and Transforming Growth Factor beta (TGFβ), two key cytokines involved in immune suppression, tumor progression, and the development of bone metastases. Although the molecule has been generated and validated in early studies, Sonnet announced in 2024 that the development program was placed on hold to prioritize resources.

Other names: anti-IL6-FHAB-anti-TGFβ

Targets

IL-6 (Interleukin 6)TGFB (GARP–latent transforming growth factor beta 1 complex)

Beyond the preview

Go deeper on SON-3015.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SON-3015.

Explore the full profile